DelveInsight’s “Hyperphosphatemia Market Insights, Epidemiology, and Market Forecast-2032“ report delivers an in-depth understanding of the Hyperphosphatemia, historical and forecasted epidemiology as well as the Hyperphosphatemia market trends in the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
The Hyperphosphatemia market report provides current treatment practices, emerging drugs, Hyperphosphatemia market share of the individual therapies, and current and forecasted Hyperphosphatemia market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Hyperphosphatemia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Hyperphosphatemia market.
Hyperphosphatemia is a condition characterized by an increase in serum phosphate level above 4.5 mg/100 mL. The condition usually occurs due to a decrement in renal function, commonly among chronic kidney disease (CKD) patients, in which phosphate levels shoot up abnormally high. Hyperphosphatemia does not usually have apparent symptoms. It is more likely that the symptoms of an underlying disease that can cause high phosphate levels, such as uncontrolled diabetes, are spotted first. More commonly, patients report uremic symptoms such as fatigue, shortness of breath, anorexia, nausea, vomiting, and sleep disturbances. If phosphate levels in the blood become too high, it may cause mineral and bone disorders and calcification. Also, hyperphosphatemia complexes serum calcium, decreasing the levels of ionized calcium and triggering PTH release, resulting in secondary hyperparathyroidism; this causes a high bone turnover state, releasing calcium from the bone to normalize the serum calcium level.
Hyperphosphatemia Epidemiology Insights
Rastogi et al. (2021) provided strategies to control hyperphosphatemia based on a systematic literature review of clinical trials and real-world observational data on phosphorus control in hemodialysis patients with CKD-mineral bone disorder (CKD-MBD). The study stated that although less than 5% of people with normal kidney function or those in CKD stages 1 and 2 exhibit hyperphosphatemia, the prevalence increases in CKD stage 3b and becomes incrementally higher in stages 4 (∼20%) and 5 (∼40%). By the time a patient receives dialysis, they are highly likely to be hyperphosphatemic.
In 2021, in the United States, the prevalence of ESRD was approximately 803,000, and patients with ESRD on dialysis accounted for approximately 570,000 cases.
In the United States, the patients with Stage 3–5 CKD accounted for around 2,359,000 in 2021.
In the United States, in 2021, accounted for approximately 484,000 prevalent cases of hyperphosphatemia in ESRD patients undergoing dialysis. Among EU4 countries, Germany had the highest number of prevalent cases of hyperphosphatemia in ESRD patients undergoing dialysis, which was around 55,000 cases in 2021. Whereas, Spain accounted for the least number of prevalent cases of hyperphosphatemia in ESRD patients undergoing dialysis, which were around 23,000 cases in 2021.
Click here to learn more about the Hyperphosphatemia Market Landscape
The Report Covers the Hyperphosphatemia Epidemiology Segmented by:
Hyperphosphatemia is prevalent in cases
Hyperphosphatemia prevelant cases
Hyperphosphatemia stage-specific distribution
Hyperphosphatemia number of patients undergoing dialysis
Hyperphosphatemia Market Outlook
The Hyperphosphatemia market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Hyperphosphatemia market trends by analyzing the impact of current Hyperphosphatemia therapies on the market, unmet needs, drivers and barriers, and demand for better technology. This segment gives a thorough detail of the Hyperphosphatemia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion, and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Hyperphosphatemia market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Hyperphosphatemia market in 7MM is expected to witness a major change in the study period 2019-2032.
Key Companies Working in the Hyperphosphatemia Market
Vifor Fresenius Medical Care Renal Pharma
And many others
Hyperphosphatemia Therapies Covered and Analyzed in the Report:
Fosrenol (Lanthanum Carbonate)
And many others
Learn more about the Hyperphosphatemia Key Companies and Emerging Therapies in the Hyperphosphatemia Market
Table of Contents
Executive Summary of Hyperphosphatemia
Disease Background and Overview
Epidemiology and patient population
Hyperphosphatemia Emerging Therapies
Hyperphosphatemia Market Outlook
Market Access and Reimbursement of Therapies
Learn about the detailed offerings of the report @ Hyperphosphatemia Market Outlook
Hyperphosphatemia Epidemiology Forecast to 2032
DelveInsight’s “Hyperphosphatemia – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Hyperphosphatemia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Trending Reports by DelveInsight
Adalimumab Biosimilar Market
Arbovirus Infection Market
Artificial Pancreas Device System Market
Dental Equipment Market
Gluten Sensitivity Market
Inflammatory Bowel Disease Market
Mayus Kinase Jak Inhibitors Market
Mild Dry Eye Market
Oncolytic Virus Cancer Therapy Market
Pyoderma Gangrenosum Market
Transdermal Drug Delivery Devices Market
Intrathecal Pumps Market
Hedgehog Pathway Inhibitors Market
Yellow Fever Market
Laryngeal Cancer Market
Female Infertility Market
Gender Dysphoria Market
Chronic Brain Damage Market
Spain Healthcare Outlook Market
Malignant Fibrous Histiocytoma Market
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States